Cantargia AB (publ)

OM:CANTA Stock Report

Market Cap: SEK 332.3m

Cantargia Valuation

Is CANTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CANTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CANTA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CANTA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CANTA?

Key metric: As CANTA is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CANTA. This is calculated by dividing CANTA's market cap by their current book value.
What is CANTA's PB Ratio?
PB Ratio6.8x
BookSEK 48.94m
Market CapSEK 332.29m

Price to Book Ratio vs Peers

How does CANTA's PB Ratio compare to its peers?

The above table shows the PB ratio for CANTA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average29.4x
ALZ Alzinova
2.6x-39.4%SEK 340.6m
ONCO Oncopeptides
2.6x35.8%SEK 356.8m
SANION Saniona
94.6x40.2%SEK 655.6m
CURAS Curasight
17.6xn/aDKK 234.7m
CANTA Cantargia
6.8x-3.4%SEK 334.3m

Price-To-Book vs Peers: CANTA is good value based on its Price-To-Book Ratio (6.8x) compared to the peer average (29.4x).

Price to Book Ratio vs Industry

How does CANTA's PB Ratio compare vs other companies in the SE Biotechs Industry?

8 CompaniesPrice / BookEstimated GrowthMarket Cap
EXPRS2 ExpreS2ion Biotech Holding
0.6x-11.9%US$3.60m
SCOL Scandion Oncology
0.4x69.7%US$1.49m
DIABIO Diagonal Bio
0.5xn/aUS$1.12m
CYXO Cyxone
0.4xn/aUS$1.07m
CANTA 6.8xIndustry Avg. 2.4xNo. of Companies10PB02.44.87.29.612+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CANTA is expensive based on its Price-To-Book Ratio (6.8x) compared to the Swedish Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is CANTA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CANTA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CANTA's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CANTA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 1.82
SEK 8.33
+357.9%
28.3%SEK 10.00SEK 5.00n/a3
Nov ’25SEK 3.06
SEK 12.33
+303.1%
13.8%SEK 14.00SEK 10.00n/a3
Oct ’25SEK 3.13
SEK 12.33
+294.0%
13.8%SEK 14.00SEK 10.00n/a3
Sep ’25SEK 3.99
SEK 12.67
+217.8%
16.2%SEK 15.00SEK 10.00n/a3
Aug ’25SEK 3.61
SEK 12.67
+251.3%
16.2%SEK 15.00SEK 10.00n/a3
Jul ’25SEK 4.41
SEK 12.67
+187.4%
16.2%SEK 15.00SEK 10.00n/a3
Jun ’25SEK 4.80
SEK 12.67
+163.9%
16.2%SEK 15.00SEK 10.00n/a3
May ’25SEK 3.34
SEK 12.67
+279.7%
16.2%SEK 15.00SEK 10.00n/a3
Apr ’25SEK 3.49
SEK 12.67
+262.9%
16.2%SEK 15.00SEK 10.00n/a3
Mar ’25SEK 2.72
SEK 12.67
+365.7%
16.2%SEK 15.00SEK 10.00n/a3
Feb ’25SEK 3.47
SEK 13.67
+294.1%
24.1%SEK 18.00SEK 10.00n/a3
Jan ’25SEK 3.74
SEK 13.67
+265.6%
24.1%SEK 18.00SEK 10.00n/a3
Dec ’24SEK 3.54
SEK 13.67
+286.5%
24.1%SEK 18.00SEK 10.00n/a3
Nov ’24SEK 3.43
SEK 14.00
+308.4%
26.7%SEK 19.00SEK 10.00SEK 3.063
Oct ’24SEK 4.26
SEK 14.00
+228.6%
26.7%SEK 19.00SEK 10.00SEK 3.133
Sep ’24SEK 4.12
SEK 14.00
+240.0%
26.7%SEK 19.00SEK 10.00SEK 3.993
Aug ’24SEK 5.05
SEK 17.00
+236.6%
30.8%SEK 26.00SEK 13.00SEK 3.614
Jul ’24SEK 4.08
SEK 17.00
+316.7%
30.8%SEK 26.00SEK 13.00SEK 4.414
Jun ’24SEK 4.68
SEK 17.00
+262.9%
30.8%SEK 26.00SEK 13.00SEK 4.804
May ’24SEK 6.09
SEK 17.00
+179.1%
30.8%SEK 26.00SEK 13.00SEK 3.344
Apr ’24SEK 6.78
SEK 17.67
+160.8%
33.4%SEK 26.00SEK 13.00SEK 3.493
Mar ’24SEK 7.82
SEK 20.00
+155.8%
24.5%SEK 26.00SEK 14.00SEK 2.723
Feb ’24SEK 6.08
SEK 22.00
+261.8%
9.1%SEK 24.00SEK 20.00SEK 3.472
Jan ’24SEK 3.08
SEK 22.00
+614.3%
9.1%SEK 24.00SEK 20.00SEK 3.742
Dec ’23SEK 3.44
SEK 22.00
+539.5%
9.1%SEK 24.00SEK 20.00SEK 3.542

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

PMD Device Solutions

SEK 35.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.36

7D

-2.9%

1Y

n/a

Camurus

SEK 32.6b

A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally.

CAMX

SEK 553.50

7D

0.6%

1Y

22.2%

Corline Biomedical

SEK 137.5m

Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.

CLBIO

SEK 6.40

7D

-7.5%

1Y

-48.2%